RNA-targeting therapeutics hold promise for accessing traditionally undruggable proteins, but conventional methods fall short in chemical space coverage. X-Chem’s patent-pending mirror-image RNA-targeted DEL screening breaks these barriers, offering broad chemical diversity, increased signal to noise ratio for hit identification, and a powerful new path to RNA drug discovery.

Machine Learning (ML) can only be powerful if the training data is of good quality. With HITMiner, we leverage our impeccably diverse library decks and robust informatics pipeline to transform experimental measurements from billions of compounds into rich datasets. Using these expert-curated datasets as
the training data for our multi-representation hub—ArtemisAI, our partners can attain series of chemically diverse series from virtual catalogs of their choice to jumpstart their campaigns.

With recent FDA approvals of covalent drugs (e.g. Zanubrutinib, Ritlecitinib), covalent targeting is improving patient outcomes. By forming irreversible bonds with protein targets, covalent inhibitors offer enhanced potency, prolonged halflife, and the potential to address therapeutically relevant mutations or difficult-to-target proteins.

X-Chem has an unrivaled track record of excellence, with nearly 100 licensed programs in DNA-encoded library (DEL)-driven discovery. Tapping into our deep well of experience, we developed ReadiBLOX — building blocks specifically designed for DEL synthesis. Our expansive catalog of ReadiBLOX encompasses a wide array of shapes, functional groups and synthetic strategies, and we regularly add to the ReadiBLOX list with our latest DEL synthesis innovations.

As DNA-encoded library (DEL) technology becomes increasingly embraced as a frontline screening tool, more and more companies seek to develop a DEL capability. They want the flexibility and scalability that comes from internally operating the platform. One perceived impediment, however, is the time and cost of creating a DEL collection of sufficient scope, quality and diversity to drive successful hit generation. The upfront costs of establishing the capability can be substantial:

DNA-encoded library (DEL) technology is increasingly becoming a mature and prominent approach to early-stage drug discovery. In contrast to conventional high-throughput screening approaches, DEL screening simultaneously interrogates billions of compounds in a single assay. X-Chem’s Custom Library Services help drug developers more quickly and efficiently discover molecules which will improve human health.

What Is Targeted Protein Degradation?
Targeted protein degradation (TPD) is one of the most exciting concepts in drug discovery to come along in the last 25 years. It holds the promise of not just inhibiting targeted proteins, but of wiping them out altogether. The power of TPD comes from harnessing the cell’s mechanisms for protein housekeeping and repurposing them to target a protein implicated in disease.

No other partner understands DEL like X-Chem — our experts invented DEL-driven drug discovery and help you leverage it with unprecedented speed and clarity.

Once billions of compounds have been screened against your target with our groundbreaking DNA-encoded library (DEL) screening platform, what’s next?

The X-Chem medicinal chemistry and bioassay teams put their extensive experience to work, converting your screening results to outstanding drug leads and candidates. Since quality and success go hand in hand, we concentrate intensively on quality through multiparameter optimization. Rather than just chasing potency, our teams focus on the physical properties and developability of your hits from day one.

Designed for researchers in emerging pharma and biotech, X-Chem’s DELflex partnership model provides access to our world-leading DNA-encoded library (DEL) screening platform. With DELflex, you can rapidly explore billions of small molecules, leveraging cutting-edge technology and expert guidance to streamline drug discovery with speed, precision, and flexibility.

DELcore offers an unparalleled premium, exclusive partnership that drives rapid, high-impact drug discovery. Partners access X-Chem’s most expansive DNAencoded libraries (DEL)—over 225 billion molecules of proprietary chemistries designed for hit identification.

As a DELcore partner, you have the unique opportunity to own the exclusive rights to the active compounds identified during the discovery process. This gives you the ability to develop these compounds as part of your own portfolio, ensuring full control over your discoveries and future therapeutic development.